After signing up, you'll start to receive regular news updates from us.
Calibrant Biosystems Announces Cooperative R&D Agreement with the Armed Forces Institute of Pathology
Complete the form below to unlock access to ALL audio articles.
Calibrant Biosystems announced that the company has signed a Cooperative Research and Development Agreement (CRADA) with the Armed Forces Institute of Pathology (AFIP) to explore the use of Calibrant’s novel Gemini™ proteomics technology in the discovery and development of novel protein biomarkers. The AFIP is an agency of the United States Department of Defense, whose mission is consultation, education and research.
Under the CRADA, the collaboration will leverage Calibrant’s proteomic technologies for the purposes of evaluating and validating protein markers for a variety of major, unmet medical needs. AFIP’s Tissue Microarray Laboratory will produce standard and custom tissue microarrays in agreement with Calibrant’s specifications. The initial project will be in the area of brain cancer, with the ultimate goal of identifying predictive markers for personalized medicine.
"Working in partnership with the AFIP via this CRADA, offers an excellent way to conduct high-throughput validation on a large population set of carefully chosen samples,” said Dr. Michael L. Salgaller, Chief Operating Officer at Calibrant.
“This collaboration should expedite the search for novel markers or sets of markers of disease – permitting more sensitive and targeted detection, diagnosis and prognosis,” added Dr. Satya Saxena, Vice President for Research.
Calibrant Biosystems is a Gaithersburg, MD biotechnology company specializing in targeted drug discovery from clinical tissue specimens. Calibrant’s advanced Gemini™ discovery platform, which is compatible with both fresh and formalin-fixed archival tissues, provides the ability to comparatively map protein networks between different cell types within a single tissue section.
With an initial focus on monoclonal antibody drug development in oncology, Calibrant is leveraging the Gemini™ platform for the development of first-in-class therapeutics and biomarkers for cancer and other major medical needs.
